Medivir Valuation Multiples

Medivir Overview

About Medivir

Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

Founded

1988

HQ

Employees

10

Website

medivir.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $869K

EBITDA: ($5M)

EV

$115M

Valuation Multiples

Multiples.vc

Start free trial

Medivir Financials

Medivir reported last 12-month revenue of $869K and negative EBITDA of ($5M).

In the same LTM period, Medivir generated $869K in gross profit, ($5M) in EBITDA losses, and had net loss of ($9M).

Medivir P&L

In the most recent fiscal year, Medivir reported revenue of $949K and EBITDA of ($3M).

Medivir expects next 12-month revenue of XXX and NTM EBITDA of XXX

Medivir Stock Performance

Medivir has current market cap of $127M, and enterprise value of $115M.

Medivir's stock price is $0.24.

Medivir Valuation Multiples

Medivir trades at 132.1x EV/Revenue multiple, and (24.5x) EV/EBITDA.

Medivir Financial Valuation Multiples

As of April 17, 2026, Medivir has market cap of $127M and EV of $115M.

Equity research analysts estimate Medivir's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medivir has a P/E ratio of (13.4x).

Medivir Margins & Growth Rates

Medivir's revenue in the last 12 month declined by (22%).

Medivir's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.

Medivir's rule of 40 is (1304%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medivir's rule of X is (1345%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Medivir Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Medivir M&A Activity

Medivir acquired XXX companies to date.

Last acquisition by Medivir was on XXXXXXXX, XXXXX. Medivir acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Medivir Investment Activity

Medivir invested in XXX companies to date.

Medivir made its latest investment on XXXXXXXX, XXXXX. Medivir invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).